Yusuf Nass
عضو نشط
- التسجيل
- 7 أبريل 2014
- المشاركات
- 36
ISR
السعر الحالي 2.68
الهدف 5
ومسألة وقت إن شاء الله
الشركة في نمو وباب المفاجآت مفتوح كونها طبية
The positive developments led to analysts at Maxim raising price target on IsoRay shares to $5 from $3.50. The stock is currently trading at around $2.75. Maxim analysts have a buy rating on the stock. The analysts noted the fundamental attributes of Cesium-131, which include higher average energy and a relatively shorter half-life than other commonly used brachytherapy isotopes, will eventually lead to conversion and adoption by key opinion leaders although it will take time. The analysts further said in a research note that IsoRay’s further growth will likely be driven by increasing adoption in non-prostate cancer treatment.
السعر الحالي 2.68
الهدف 5
ومسألة وقت إن شاء الله
الشركة في نمو وباب المفاجآت مفتوح كونها طبية
The positive developments led to analysts at Maxim raising price target on IsoRay shares to $5 from $3.50. The stock is currently trading at around $2.75. Maxim analysts have a buy rating on the stock. The analysts noted the fundamental attributes of Cesium-131, which include higher average energy and a relatively shorter half-life than other commonly used brachytherapy isotopes, will eventually lead to conversion and adoption by key opinion leaders although it will take time. The analysts further said in a research note that IsoRay’s further growth will likely be driven by increasing adoption in non-prostate cancer treatment.
